Company News: Pfizer

Share this article:
Pfizer CEO Jeff Kindler told shareholders that no one Pfizer product "is expected to account for more than 10% of our annual revenue, once Lipitor loses US exclusivity" late next year. Lipitor accounted for 23%, or $11 billion, of the company's annual revenue in 2009. Preliminary voting results on a handful of topics -- excluding stockholders from advising on executive pay, confirming the company's public accounting firm of record (KPMG), confirming company directors and a shrinking of the percent of shares required to hold special shareholder meetings were all passed by large margins. Only one initiative was rejected -- a proposal put forth by Evelyn Y. Davis -- that would have halted the practice of offering executives stock options. The annual shareholders meeting was held in Cleveland.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations -- which have been piling up -- have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.